Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 versus pembrolizumab in previously untreated unresectable or metastatic acral or mucosal melanoma
CTR20250280Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in melanoma, mucosal melanoma (MM), acral lentiginous melanoma (ALM), sponsored by InnoCare Pharma. Started Feb 2025; status: active.
02
Drugs
IBI363
03
Conditions
melanomamucosal melanoma (MM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on CTR20250280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250280.